Abstract

The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.

Keywords

MedicinePandemicClinical trialIntensive care medicineOseltamivirCoronavirus disease 2019 (COVID-19)CoronavirusDiseaseRandomized controlled trialOff-label useVirologyInfectious disease (medical specialty)PharmacologyInternal medicine

MeSH Terms

Adenosine MonophosphateAdrenal Cortex HormonesAlanineAmidesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntiviral AgentsAzithromycinBetacoronavirusCOVID-19ChloroquineCoronavirus InfectionsHumansHydroxychloroquineImmunoglobulinsImmunologic FactorsIndolesLopinavirOseltamivirPandemicsPneumoniaViralPyrazinesRibavirinRitonavirSARS-CoV-2Withholding TreatmentCOVID-19 Drug Treatment

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
review
Volume
323
Issue
18
Pages
1824-1836
Citations
2440
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2440
OpenAlex
132
Influential
1034
CrossRef

Cite This

James M. Sanders, Marguerite L. Monogue, Tomasz Z. Jodlowski et al. (2020). Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). JAMA , 323 (18) , 1824-1836. https://doi.org/10.1001/jama.2020.6019

Identifiers

DOI
10.1001/jama.2020.6019
PMID
32282022

Data Quality

Data completeness: 81%